Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) shares spiked 8.60 percent to close at $2.40 a share Thursday. The stock traded between $2.27 and $2.51 on volume of 7.51 million shares traded. The company announced the pricing of a public offering of 11,325,000 shares of its common stock at a price of $2.21 per share. Shares of Catalyst Pharmaceutical Partners are up approximately 23.0 percent year-to-date.
Get more information on Catalyst Pharmaceutical and free access to the in-depth equity report at: www.FiveStarEquities.com/CPRX
Gastar Exploration, Inc. (NYSEMKT: GST) shares jumped 4.50 percent to close at $6.27 a share Thursday. The stock traded between $6.08 and $6.59 on volume of 2.17 million shares traded. The company recently held an analyst meeting to discuss its operations in the Marcellus and Utica plays in Appalachia and the Hunton play in Oklahoma. Shares of Gastar Exploration are up approximately 8.0 percent year-to-date.
Get more information on Gastar Exploration and free access to the in-depth equity report at: www.FiveStarEquities.com/GST
Response Genetics, Inc. (NASDAQ: RGDX) shares surged 18.33 percent to close at $1.42 a share Thursday. The stock traded between $1.34 and $1.56 on volume 9.82 million shares traded. The company announced that it has signed contracts with six additional health plans across 10 states. Shares of Response Genetics are up approximately 22.0 percent year-to-date.
Get more information on Response Genetics and free access to the in-depth equity report at: www.FiveStarEquities.com/RGDX
VirnetX Holding Corporation (NYSEMKT: VHC) shares increased 5.31 percent to close at $15.48 a share Thursday. The stock traded between $15.10 and $15.82 on volume 966,950 shares traded. The company recently announced that it had strengthened its global patent portfolio with four new patents. Shares of VirnetX are down approximately 20.0 percent year-to-date.
Get more information on VirnetX free access to the in-depth equity report at: www.FiveStarEquities.com/VHC
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]